Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Liabilities and Shareholders Equity (2016 - 2025)

Rocket Pharmaceuticals' Liabilities and Shareholders Equity history spans 10 years, with the latest figure at $330.4 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 37.38% year-over-year to $330.4 million; the TTM value through Dec 2025 reached $1.6 billion, down 14.82%, while the annual FY2025 figure was $330.4 million, 37.38% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $330.4 million at Rocket Pharmaceuticals, down from $368.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $598.8 million in Q3 2023 and bottomed at $330.4 million in Q4 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $484.0 million (2021), against an average of $480.0 million.
  • The largest annual shift saw Liabilities and Shareholders Equity surged 58.05% in 2021 before it crashed 37.38% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $497.0 million in 2021, then increased by 11.02% to $551.8 million in 2022, then increased by 2.63% to $566.3 million in 2023, then decreased by 6.82% to $527.7 million in 2024, then tumbled by 37.38% to $330.4 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Liabilities and Shareholders Equity are $330.4 million (Q4 2025), $368.0 million (Q3 2025), and $421.0 million (Q2 2025).